SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer Journal Article
| Authors: | Tammela, J.; Jungbluth, A. A.; Qian, F.; Santiago, D.; Scanlan, M. J.; Keitz, B.; Driscoll, D.; Rodabaugh, K.; Lele, S.; Old, L. J.; Odunsi, K. |
| Article Title: | SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer |
| Abstract: | SCP-1 is a novel tumor antigen that belongs to the growing family of cancer/testis (CT) antigens, and it is a potential target for immunotherapy. In an effort to determine the expression of SCP-1 in epithelial ovarian cancer (EOC), one-step RT-PCR was performed with RNA from epithelial ovarian tumor tissues and with two normal ovarian surface epithelial cell lines. We used immunohistochemistry (IHC) to investigate SCP-1 expression in paraffin-fixed EOC samples and ELISA to test sera from a subgroup of patients for SCP-1 antibody. SCP-1 was expressed in 15 out of 100 (15%) primary tumors, as determined by RT-PCR. The normal ovarian surface epithelial cell lines were negative for SCP-1 expression, as were a panel of other normal tissues. None of the patients whose tumors were determined to be SCP-1 positive by RT-PCR expressed the antigen by IHC or demonstrated a humoral immune response by ELISA. Tumors that expressed SCP-1 mRNA tended to have a higher grade than those that did not (P = 0.03). There was a significant decrease in survival time (P = 0.004) for patients with SCP-1 mRNA-positive tumors compared to those with SCP-1 mRNA-negative tumors [median 25 mo, 95% confidence interval (CI) 0-56 mo; and median 97 mo, CI 32-162 mo, respectively]. The present study shows that SCP-1 mRNA expression in patients with EOC is associated with a poorer chance of survival. These findings imply that further evaluation of SCP-1 as a potential target for vaccine therapy in EOC is warranted. |
| Keywords: | immunohistochemistry; adult; cancer survival; controlled study; human tissue; aged; unclassified drug; human cell; major clinical study; cancer grading; ovarian cancer; antigen expression; reverse transcription polymerase chain reaction; ovary cancer; gene expression; cell line; enzyme linked immunosorbent assay; confidence interval; rna; survival time; statistical significance; immunotherapy; messenger rna; cancer testis antigen; epithelium; humoral immunity; paraffin; rt-pcr; prognosis; human; article; scp-1; stromal cell derived protein 1 |
| Journal Title: | Cancer Immunity |
| Volume: | 4 |
| ISSN: | 1424-9634 |
| Publisher: | Academy of Cancer Immunology |
| Date Published: | 2004-10-18 |
| Start Page: | 10 |
| End Page: | 20 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 15487888 |
| DOI/URL: | |
| Notes: | Cancer Immun. -- Cited By (since 1996):11 -- Export Date: 16 June 2014 -- Source: Scopus |
Citation Impact
Related MSK Work